-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In addition to the latest academic progress, what else did we gain from the ADA Essentials China Tour? "Best of ADA China" is the essence of the American Diabetes Association (ADA) China Tour.
It is committed to sharing and exchanging the academic essence of the annual ADA conference.
The content involves the most cutting-edge research results in the field of diabetes.
It is an excellent place to discuss treatment concepts and clinical practice together.
Opportunity
.
Three years have passed since the implementation of the ADA Essence China Project, which has brought a lot of inspiration to clinicians
.
On the occasion of the third anniversary, the "Courtesy of the Future, ADA's Essence of China Tour, Three Years of Review and Prospect of the Humanities Salon" was successfully held
.
Professor Yu Miao from Peking Union Medical College Hospital served as the host, Professor Ji Linong from Peking University People’s Hospital, Professor Yang Wenying from China-Japan Friendship Hospital, Professor Hong Tianpei from Peking University Third Hospital, Professor Xiao Xinhua from Peking Union Medical College Hospital, and the American Diabetes Association as the medical & scientific chair-designate Professor Guillermo Umpierrez gathered online and offline.
Looking back three years, what are the thoughts of the big coffee? Figure ADA Essence China Tour’s third anniversary salon impacts clinical practice.
These ADA topics should not be forgotten.
Professor Ji Linong first pointed out that the ADA Essence China Tour, funded by Eli Lilly and Company, is an activity organized independently by ADA.
In the past three years, The Chinese academic community introduced the latest diabetes research, the Banting Scientific Achievement Award, Outstanding Scientific Achievement Award, Albert Renold Award and other major awards, covering the entire field of diabetes diagnosis and treatment including diagnosis, treatment, and management
.
As a clinician, what is most memorable for Professor Ji Linong is the information he has obtained in the research and development of new hypoglycemic drugs
.
For example, sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RA) have been found to have good heart and (or) kidney effects in addition to hypoglycemic effects.
Protective effects
.
The multi-target glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist Tirzepatide (TZP) showed better body weight and blood sugar than GLP-1RA The management effect brings new information to clinicians and new hope for us to better manage diabetes
.
Professor Yang Wenying believes that through the study of related studies in the past few years, we have learned that SGLT2 inhibitors and GLP-1RA two major types of new diabetes drugs have relevant evidence for improving long-term major cardiovascular adverse events
.
Combined with the latest clinical research, the Diabetes Branch of the Chinese Medical Association (CDS) updated the "Guidelines for the Prevention and Treatment of Type 2 Diabetes in China" (hereinafter referred to as the "CDS Guidelines") in 2020.
This clinical research promotes the concept of updating the guidelines and keeping pace with the times Professor Yang Wenying was deeply impressed
.
Professor Hong Tianpei believes that the ADA Essentials China Tour has delivered the latest information about ADA, so that we can get the latest diabetes-related information without going to the scene and listening to the whole process
.
The cardiovascular safety evidence of hypoglycemic drugs is the most memorable study by Professor Hong Tianpei.
For patients with high risk of atherosclerotic cardiovascular disease (ASCVD), both SGLT2 inhibitors and GLP-1RA have shown very good treatments Drugs targeting GIP and GLP-1 also show good therapeutic potential, and their future is worth looking forward to
.
Professor Xiao Xinhua believes that the Cardiovascular Outcomes Trials (CVOT) of type 2 diabetes drugs is a major research in the field of diabetes in recent years.
Professor Xiao Xinhua’s most memorable is the REWIND study (dulaglutide CVOT), which is bold The superior design and the targeted primary and secondary prevention populations of ASCVD allow us to initiate treatment earlier to reduce the risk of cardiovascular events in patients
.
Professor Yu Miao believes that from 2020 until now, the outbreak of the epidemic has posed a very high challenge to the medical system, and under the background of normalization of prevention and control, it has also given medical staff a lot of practical experience and inspiration
.
Although the epidemic has pressed the stop button on us, the diagnosis and treatment of diabetic patients is still urgent, and we are also required to keep pace with the times and adjust the strategy of diabetes diagnosis and treatment
.
During the past three years, ADA Essence China has broken through the limitations of the time and space of the epidemic, and brought us many unforgettable studies that affect clinical practice.
At the same time, it has screened the most clinically significant topics for preaching, and hopes to be conducted by experts in the field of diabetes in China in the future.
Further refinement brings a higher level of "brainstorming
.
"
Professor Zhu Dalong from Drum Tower Hospital of Nanjing University School of Medicine and Professor Guo Lixin from Beijing Hospital also shared their memories and views on the ADA essence of China after the event
.
Professor Zhu Dalong mentioned that the ADA Essence China Tour has allowed us to realize that the two countries have similarities in the treatment principles for diabetic patients
.
In recent years, a number of studies on SGLT2 inhibitors and GLP-1RA have been published on the ADA, which has driven the update of many guidelines including the "CDS Guidelines".
Whether glycosylated hemoglobin (HbA1c) is up to standard, as long as there is no contraindication, GLP-1RA or SGLT2 inhibitors with evidence of ASCVD benefit should be added on the basis of metformin
.
Professor Guo Lixin pointed out that our treatment concept for diabetes should be updated from blood glucose control to comprehensive metabolic abnormality control.
The data of ADA essence in China for three years has convinced us that some drugs can reduce the risk of cardiovascular disease in addition to the benefits of lowering blood sugar.
The relevant guidelines have also updated relevant drug recommendations
.
In the future, I hope to conduct further refinement and analysis of related content, focusing on blood sugar, but going beyond blood sugar, to truly improve the clinical outcome of diabetes and achieve good control of the entire life cycle of diabetes patients
.
Professor Umpierrez pointed out that the epidemic has brought many difficulties to on-site academic exchanges in the field of diabetes.
The ADA Essence China Tour serves as a bridge to help the Chinese and American academic communities maintain in-depth communication and exchanges.
He hopes to see more Chinese academic research in ADA in the future.
Shine at the annual meeting
.
Diabetes medication plans tend to be diversified.
What changes can we expect that these changes in the past few years have brought about new research and new developments in the field of diabetes? Professor Ji Linong believes that the patient-centered concept is always worth promoting.
In addition to referring to the results of diabetes clinical trials, it is also necessary to consider the social environment, economic income, and treatment compliance of patients
.
In the future, we will continue to explore how to jointly apply new hypoglycemic drugs, and the relevant research results are worth looking forward to
.
Professor Yang Wenying pointed out that many CVOT studies have brought us surprising results, but the study populations included in different CVOT studies are different.
For example, the populations included in the REWIND study all have cardiovascular risk factors, but some patients have not been diagnosed with cardiovascular disease, that is At the same time, the primary and secondary prevention populations are included.
The positive results give us more confidence in expanding the application population of laglycotide.
Diabetic patients with 2 or more cardiovascular risk factors can start treatment
.
Looking forward to more large-sample studies in the future, let us make good use of new-type hypoglycemic drugs
.
Professor Hong Tianpei looks forward to more new diabetes treatment drugs in the future.
The number of diabetes patients is still increasing.
Due to the complex pathogenesis of the disease, we need both traditional hypoglycemic drugs and new drugs, and look forward to the emergence of "diabetes terminator"
.
Professor Xiao Xinhua believes that in the future, the field of diabetes should carry out two different researches
.
One is the continuous development of new drugs with the in-depth understanding of the pathogenesis of diabetes
.
The second is to carry out more in-depth research and development of existing drugs, clarify the population that is more suitable for such drug treatment, and strive to achieve the goal of better curative effect and fewer adverse reactions
.
In addition, with the aid of the latest artificial intelligence and Internet medical technology, scientific management of diabetic patients is also of great significance
.
Professor Zhu Dalong looks forward to seeing more Chinese clinical studies on the ADA in the future, obtaining evidence-based evidence for the application of various new diabetes drugs in the Chinese population, and expressing the voice of Chinese scholars on the international stage
.
In addition to drug treatment, we cannot ignore the education of diabetic patients
.
Only by paying equal attention to multiple aspects can we manage diabetic patients well .
Professor Guo Lixin expects that new drugs such as the GIP/GLP-1 receptor dual agonist TZP can accumulate more evidence in future studies
.
This is a class of drugs with very promising applications.
It has good benefits in weight loss, hypoglycemia, and treatment of fatty liver.
Because the drug has been available for a short time, evidence of its efficacy and safety needs to be accumulated
.
Of course, with the development of new drugs, we have further realized that diabetes is a very complex disease.
The road to comprehensive control is a long way to go
.
Summary The management of diabetic patients is a complex issue.
Evidence-based evidence-driven changes in diagnosis and treatment concepts, more "weapons" brought about by drug research and development, changes in the availability and affordability of drugs, and improvements in management technology platforms will continue.
Improve the ecological chain of diagnosis and treatment of diabetic patients
.
In the post-epidemic era, ADA Essence China will continue to assist clinical continuing education in the field of diabetes, discuss clinical scientific research and transformation, and further dialogues with the world to discuss cutting-edge disease solutions and share "Chinese experience" in diabetes management
.
*The copyright of this article belongs to the original author.
If you need to reprint, please contact the original author for authorization
It is committed to sharing and exchanging the academic essence of the annual ADA conference.
The content involves the most cutting-edge research results in the field of diabetes.
It is an excellent place to discuss treatment concepts and clinical practice together.
Opportunity
.
Three years have passed since the implementation of the ADA Essence China Project, which has brought a lot of inspiration to clinicians
.
On the occasion of the third anniversary, the "Courtesy of the Future, ADA's Essence of China Tour, Three Years of Review and Prospect of the Humanities Salon" was successfully held
.
Professor Yu Miao from Peking Union Medical College Hospital served as the host, Professor Ji Linong from Peking University People’s Hospital, Professor Yang Wenying from China-Japan Friendship Hospital, Professor Hong Tianpei from Peking University Third Hospital, Professor Xiao Xinhua from Peking Union Medical College Hospital, and the American Diabetes Association as the medical & scientific chair-designate Professor Guillermo Umpierrez gathered online and offline.
Looking back three years, what are the thoughts of the big coffee? Figure ADA Essence China Tour’s third anniversary salon impacts clinical practice.
These ADA topics should not be forgotten.
Professor Ji Linong first pointed out that the ADA Essence China Tour, funded by Eli Lilly and Company, is an activity organized independently by ADA.
In the past three years, The Chinese academic community introduced the latest diabetes research, the Banting Scientific Achievement Award, Outstanding Scientific Achievement Award, Albert Renold Award and other major awards, covering the entire field of diabetes diagnosis and treatment including diagnosis, treatment, and management
.
As a clinician, what is most memorable for Professor Ji Linong is the information he has obtained in the research and development of new hypoglycemic drugs
.
For example, sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RA) have been found to have good heart and (or) kidney effects in addition to hypoglycemic effects.
Protective effects
.
The multi-target glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist Tirzepatide (TZP) showed better body weight and blood sugar than GLP-1RA The management effect brings new information to clinicians and new hope for us to better manage diabetes
.
Professor Yang Wenying believes that through the study of related studies in the past few years, we have learned that SGLT2 inhibitors and GLP-1RA two major types of new diabetes drugs have relevant evidence for improving long-term major cardiovascular adverse events
.
Combined with the latest clinical research, the Diabetes Branch of the Chinese Medical Association (CDS) updated the "Guidelines for the Prevention and Treatment of Type 2 Diabetes in China" (hereinafter referred to as the "CDS Guidelines") in 2020.
This clinical research promotes the concept of updating the guidelines and keeping pace with the times Professor Yang Wenying was deeply impressed
.
Professor Hong Tianpei believes that the ADA Essentials China Tour has delivered the latest information about ADA, so that we can get the latest diabetes-related information without going to the scene and listening to the whole process
.
The cardiovascular safety evidence of hypoglycemic drugs is the most memorable study by Professor Hong Tianpei.
For patients with high risk of atherosclerotic cardiovascular disease (ASCVD), both SGLT2 inhibitors and GLP-1RA have shown very good treatments Drugs targeting GIP and GLP-1 also show good therapeutic potential, and their future is worth looking forward to
.
Professor Xiao Xinhua believes that the Cardiovascular Outcomes Trials (CVOT) of type 2 diabetes drugs is a major research in the field of diabetes in recent years.
Professor Xiao Xinhua’s most memorable is the REWIND study (dulaglutide CVOT), which is bold The superior design and the targeted primary and secondary prevention populations of ASCVD allow us to initiate treatment earlier to reduce the risk of cardiovascular events in patients
.
Professor Yu Miao believes that from 2020 until now, the outbreak of the epidemic has posed a very high challenge to the medical system, and under the background of normalization of prevention and control, it has also given medical staff a lot of practical experience and inspiration
.
Although the epidemic has pressed the stop button on us, the diagnosis and treatment of diabetic patients is still urgent, and we are also required to keep pace with the times and adjust the strategy of diabetes diagnosis and treatment
.
During the past three years, ADA Essence China has broken through the limitations of the time and space of the epidemic, and brought us many unforgettable studies that affect clinical practice.
At the same time, it has screened the most clinically significant topics for preaching, and hopes to be conducted by experts in the field of diabetes in China in the future.
Further refinement brings a higher level of "brainstorming
.
"
Professor Zhu Dalong from Drum Tower Hospital of Nanjing University School of Medicine and Professor Guo Lixin from Beijing Hospital also shared their memories and views on the ADA essence of China after the event
.
Professor Zhu Dalong mentioned that the ADA Essence China Tour has allowed us to realize that the two countries have similarities in the treatment principles for diabetic patients
.
In recent years, a number of studies on SGLT2 inhibitors and GLP-1RA have been published on the ADA, which has driven the update of many guidelines including the "CDS Guidelines".
Whether glycosylated hemoglobin (HbA1c) is up to standard, as long as there is no contraindication, GLP-1RA or SGLT2 inhibitors with evidence of ASCVD benefit should be added on the basis of metformin
.
Professor Guo Lixin pointed out that our treatment concept for diabetes should be updated from blood glucose control to comprehensive metabolic abnormality control.
The data of ADA essence in China for three years has convinced us that some drugs can reduce the risk of cardiovascular disease in addition to the benefits of lowering blood sugar.
The relevant guidelines have also updated relevant drug recommendations
.
In the future, I hope to conduct further refinement and analysis of related content, focusing on blood sugar, but going beyond blood sugar, to truly improve the clinical outcome of diabetes and achieve good control of the entire life cycle of diabetes patients
.
Professor Umpierrez pointed out that the epidemic has brought many difficulties to on-site academic exchanges in the field of diabetes.
The ADA Essence China Tour serves as a bridge to help the Chinese and American academic communities maintain in-depth communication and exchanges.
He hopes to see more Chinese academic research in ADA in the future.
Shine at the annual meeting
.
Diabetes medication plans tend to be diversified.
What changes can we expect that these changes in the past few years have brought about new research and new developments in the field of diabetes? Professor Ji Linong believes that the patient-centered concept is always worth promoting.
In addition to referring to the results of diabetes clinical trials, it is also necessary to consider the social environment, economic income, and treatment compliance of patients
.
In the future, we will continue to explore how to jointly apply new hypoglycemic drugs, and the relevant research results are worth looking forward to
.
Professor Yang Wenying pointed out that many CVOT studies have brought us surprising results, but the study populations included in different CVOT studies are different.
For example, the populations included in the REWIND study all have cardiovascular risk factors, but some patients have not been diagnosed with cardiovascular disease, that is At the same time, the primary and secondary prevention populations are included.
The positive results give us more confidence in expanding the application population of laglycotide.
Diabetic patients with 2 or more cardiovascular risk factors can start treatment
.
Looking forward to more large-sample studies in the future, let us make good use of new-type hypoglycemic drugs
.
Professor Hong Tianpei looks forward to more new diabetes treatment drugs in the future.
The number of diabetes patients is still increasing.
Due to the complex pathogenesis of the disease, we need both traditional hypoglycemic drugs and new drugs, and look forward to the emergence of "diabetes terminator"
.
Professor Xiao Xinhua believes that in the future, the field of diabetes should carry out two different researches
.
One is the continuous development of new drugs with the in-depth understanding of the pathogenesis of diabetes
.
The second is to carry out more in-depth research and development of existing drugs, clarify the population that is more suitable for such drug treatment, and strive to achieve the goal of better curative effect and fewer adverse reactions
.
In addition, with the aid of the latest artificial intelligence and Internet medical technology, scientific management of diabetic patients is also of great significance
.
Professor Zhu Dalong looks forward to seeing more Chinese clinical studies on the ADA in the future, obtaining evidence-based evidence for the application of various new diabetes drugs in the Chinese population, and expressing the voice of Chinese scholars on the international stage
.
In addition to drug treatment, we cannot ignore the education of diabetic patients
.
Only by paying equal attention to multiple aspects can we manage diabetic patients well .
Professor Guo Lixin expects that new drugs such as the GIP/GLP-1 receptor dual agonist TZP can accumulate more evidence in future studies
.
This is a class of drugs with very promising applications.
It has good benefits in weight loss, hypoglycemia, and treatment of fatty liver.
Because the drug has been available for a short time, evidence of its efficacy and safety needs to be accumulated
.
Of course, with the development of new drugs, we have further realized that diabetes is a very complex disease.
The road to comprehensive control is a long way to go
.
Summary The management of diabetic patients is a complex issue.
Evidence-based evidence-driven changes in diagnosis and treatment concepts, more "weapons" brought about by drug research and development, changes in the availability and affordability of drugs, and improvements in management technology platforms will continue.
Improve the ecological chain of diagnosis and treatment of diabetic patients
.
In the post-epidemic era, ADA Essence China will continue to assist clinical continuing education in the field of diabetes, discuss clinical scientific research and transformation, and further dialogues with the world to discuss cutting-edge disease solutions and share "Chinese experience" in diabetes management
.
*The copyright of this article belongs to the original author.
If you need to reprint, please contact the original author for authorization
